Research programme: liver disorders therapy - ALP Life Sciences
Alternative Names: NanovesonLatest Information Update: 16 Jul 2016
At a glance
- Originator ALP Life Sciences
- Class Lipids
- Mechanism of Action Arachidonic acid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Liver disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Liver-disorders in USA
- 24 Jun 2009 Preclinical trials in Liver disorders in USA (unspecified route)